<code id='2154AD52CC'></code><style id='2154AD52CC'></style>
    • <acronym id='2154AD52CC'></acronym>
      <center id='2154AD52CC'><center id='2154AD52CC'><tfoot id='2154AD52CC'></tfoot></center><abbr id='2154AD52CC'><dir id='2154AD52CC'><tfoot id='2154AD52CC'></tfoot><noframes id='2154AD52CC'>

    • <optgroup id='2154AD52CC'><strike id='2154AD52CC'><sup id='2154AD52CC'></sup></strike><code id='2154AD52CC'></code></optgroup>
        1. <b id='2154AD52CC'><label id='2154AD52CC'><select id='2154AD52CC'><dt id='2154AD52CC'><span id='2154AD52CC'></span></dt></select></label></b><u id='2154AD52CC'></u>
          <i id='2154AD52CC'><strike id='2154AD52CC'><tt id='2154AD52CC'><pre id='2154AD52CC'></pre></tt></strike></i>

          Home / hotspot / leisure time

          leisure time


          leisure time

          author:fashion    Page View:88671
          Adam's take main illustration
          Molly Ferguson/STAT

          Biotech is awash in PIPEs.

          The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year.

          advertisement

          Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year. Crinetics Pharmaceuticals raised $350 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In